Trial Profile
Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Acute myeloid leukaemia; Idiopathic thrombocytopenic purpura; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK; Novartis Pharmaceuticals
- 03 Mar 2022 Status changed from active, no longer recruiting to completed.
- 17 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 04 Feb 2019 Status changed from active, no longer recruiting to recruiting.